An interventional study of Placebo and Glucose in Obesity, sponsored by University Hospital, Basel, Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-04-03.
Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing glucose in Obesity — 3 open to participants now, 3 under way, none of them phase 3. Glucose · Obesity.
Among the 17 studies testing glucose in Obesity, this one is the 15th largest by planned enrollment, is the only one that started in 2014, is one of 12 with no phase, and was the 7th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →3 of the 17 studies testing glucose in Obesity are open now, in 2 countries. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 18–65
Rutgers, The State University of New Jersey
Ages 40–70 · Healthy volunteers
By country, each count listing its studies:
Glucose: first FDA approval 1946 (ALCOHOL 5% AND DEXTROSE 5%). What it is approved for, and how studies give it, is on its page →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 16 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 20 across the 17 interventional studies. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 17 have an industry lead sponsor. The 10 most frequent:
University Hospital, Basel, Switzerland is the lead sponsor of 990 studies on the registry; 189 are open to participants now.
20 studies in Obesity by University Hospital, Basel, Switzerland: 3 open now, 4 under way, none of them phase 3. Of 16 finished, 0 (0%) have results posted.
Among the 20 studies in Obesity by University Hospital, Basel, Switzerland, this one is the 13th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2014, is one of 14 with no phase, and was the 10th registered.
University Hospital, Basel, Switzerland’s Obesity studies by the year they started, since 2008.
1 of the studies testing glucose in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02902198University Hospital, Basel, SwitzerlandTaste Physiology in Obese Volunteers Before and After Bariatric Surgery | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing glucose in Obesity, from their registry updates:
Among University Hospital, Basel, Switzerland’s 20 in Obesity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective is to investigate neuro-anatomical correlates of gastrointestinal taste stimulation by means of functional MRI before and after bariatric surgery. Intragastric administration of glucose, monosodium glutamate, chloroquine and placebo is followed by functional brain MRI in obese humans before and 3 months after surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single intragastric instillation of 200ml tap water via nasogastric tube
Dietary Supplement: Placebo
Single intragastric instillation of 200ml tap water via nasogastric tube
Dietary Supplement: Placebo
Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube
Dietary Supplement: Glucose
Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube
Dietary Supplement: Glucose
Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube
Dietary Supplement: Monosodium glutamate
Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube
Dietary Supplement: Monosodium glutamate
Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube
Dietary Supplement: Quinine
Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube
Dietary Supplement: Quinine
Tap water 200ml
25g Glucose in 200ml tap water
1g monosodium glutamate in 200ml tap water
17mg quinine in 200ml tap water
Effect of tastants on cerebral blood flow measured by functional brain MRI
Time frame: changes from baseline to one hour after treatment
Effect of tastants plasma glucagon-like peptide (GLP-1) concentrations
Time frame: changes from baseline to one hour after treatment
Effect of tastants plasma ghrelin concentrations
Time frame: changes from baseline to one hour after treatment
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2014 (actual). Primary completion is estimated for Dec 2026, 144 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 144 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Glucose · Sodium Glutamate · Quinine
University Hospital, Basel, Switzerland →